1-6 of 6
Sari Heitner Enschede, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Uptake of Novel Therapies into First-Line Treatment for AML Patients - EU5 Perspective

Thomas Moehler, MD PhD, Magdalena Ruiz, MD MSc, Vicky Casey, Luana Margotto Soares, Fil Manuguid, Kriti Jindal, MS, Sari Heitner Enschede, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28.
https://doi.org/10.1182/blood-2020-135921
Published: 2020
Journal Articles

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Sven de Vos, MD PhD, Lode Swinnen, MD, Mark Kozloff, MD, Ding Wang, MD PhD, Erin Reid, MD, Loretta Nastoupil, MD, Nathan Fowler, MD, Jaclyn Cordero, Diane D'Amico, Susan Diehl, Martin Dunbar, DrPH, Ming Zhu, PhD, Shekman Wong, PhD, Sari Heitner Enschede, MD, David Chien, MD, Rod A. Humerickhouse, MD PhD, Christopher Flowers, MD
Journal: Blood
Blood (2015) 126 (23): 255.
https://doi.org/10.1182/blood.V126.23.255.255
Published: 2015
Journal Articles

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Jeremy Ross, PhD, Martine Amiot, PhD, Brenda Chyla, PhD, Lisa Roberts-Rapp, Rasna Goswami, Sun Yan, Xin Huang, Anahita Bhathena, Sari Heitner Enschede, MD, Paulo Maciag, MD, Rod A. Humerickhouse, MD PhD, Evelyn McKeegan
Journal: Blood
Blood (2015) 126 (23): 2975.
https://doi.org/10.1182/blood.V126.23.2975.2975
Published: 2015
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Shaji K. Kumar, MD, Ravi Vij, MD MBA, Jonathan L. Kaufman, MD, Joseph R. Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MDPhD, Philippe Moreau, MD, Martine Amiot, PhD, Stefanie Alzate, MS, Lura Morris, BA, Jeremy Ross, PhD, Martin Dunbar, DrPH, Ming Zhu, PhD, Paulo Maciag, MD, Suresh Agarwal, PhD, Joel Leverson, PhD, Sari Heitner Enschede, MD, Rod A. Humerickhouse, MD PhD, Cyrille Touzeau, MD
Journal: Blood
Blood (2015) 126 (23): 4219.
https://doi.org/10.1182/blood.V126.23.4219.4219
Published: 2015
Journal Articles

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Stephan Stilgenbauer, MD PhD, Barbara F. Eichhorst, MD, Johannes Schetelig, MD, M.Sc, Steven Coutre, MD, John F. Seymour, MBBS, PhD, Talha Munir, MBBS, MRCP, FRCPath, Soham D. Puvvada, MD, Clemens-Martin Wendtner, MD, Andrew W. Roberts, MBBS, PhD, Wojciech Jurczak, MD, PhD, Stephen Mulligan, MBBS, PhD, FRACP, FRCPA, Sebastian Boettcher, MD, Mehrdad Mobasher, MD, Ming Zhu, PhD, Brenda Chyla, PhD, Maria Verdugo, MD, Sari Heitner Enschede, MD, Elisa Cerri, MD, Rod A. Humerickhouse, MD, PhD, Gary Gordon, MD, PhD, Michael Hallek, MD, William Wierda, MD, PhD
Journal: Blood
Blood (2015) 126 (23): LBA-6.
https://doi.org/10.1182/blood.V126.23.LBA-6.LBA-6
Published: 2015
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Philippe Moreau, MD PhD, Asher Chanan-Khan, MD, Andrew W. Roberts, MBBS, PhD, Amit B. Agarwal, MDPhD, Thierry Facon, Shaji Kumar, MD, Cyrille Touzeau, MD, David Darden, MS, Lura Morris, BA, Jeremy Ross, PhD, Ahmed H Salem, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Joel Leverson, PhD, Paulo Maciag, MD, Sari Heitner Enschede, MD, Maria Verdugo, MD, Rod A. Humerickhouse, MD PhD, Simon Harrison, MD
Journal: Blood
Blood (2015) 126 (23): 3038.
https://doi.org/10.1182/blood.V126.23.3038.3038
Published: 2015